Phenotype of peripheral blood leukocytes and survival of patients with metastatic colorectal cancer

International Journal of Biological Markers

Volumn 20, Issue 2, 2005, Pages 126-133

  Vesely P ^a   Touskova M ^a   Melichar, Bohuslav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Colorectal carcinoma; Prognosis; T lymphocytes

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD23 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; COLORIMETRY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; PHENOTYPE; PREDICTION; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE;

EID: 22944435508     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.863     Document Type: Article

References (23)

1. Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999; 48: 353-62.
2. Melichar B, Jandik P, Krejsek J, et al. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996; 82: 218-20.
3. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Inv 2001; 61: 363-70.
4. Lissoni P, Brivio F, Ferrante R, et al. Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer. Int J Biol Markers 2000; 15: 22-5.
5. Tong AW, Seamour B, Lawson JM, et al. Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 2000; 23: 463-72.
6. Berghella AM, Pellegrini P, Del Beato T, Maccarone D, Adorno D, Casciani CU. Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother Radiopharm 1996; 11: 355-61.
7. Holcombe RF, Jacobson J, Dakhil SR, et al. Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009. Cancer Immunol Immunother 1999; 48: 533-9.
8. Zaloudik J, Lauerova L, Janakova L, et al. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 1999; 46: 220-7.
9. McLeod HL, Murray HI. Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999; 79: 191-203.
10. Gennari L, Doci R, Rossetti C. Prognostic factors in colorectal cancer. Hepatogastroenterology 2000; 47: 310-4.
11. Kim SB, Fernandes LC, Saad SS. Assessment of the value of preoperative serum levels of CA242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients. Int J Biol Markers 2003; 18: 182-7.
12. Andicoechea A, Vizoso F, Alexandre E, et al. Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer. Int J Biol Markers 1998; 13: 158-64.
13. Massacesi C, Norman A, Price T, Hill M, Ross P, Cunningham D. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer 2000; 36: 2044-52.
14. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
15. Cunningham D, Hurnblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl Med 2004; 351: 337-45.
16. Melichar B, Touskova M, Blaha M, et al. Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biother Radiopharm 2002; 17: 545-52.
17. Heller G, Simonoff JS. Prediction in censored survival data: A comparison of the proportional hazards and linear regression models. Biometrics 1992; 48: 101-15.
18. Simms PE, Ellis TM. Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocytes activation. Clin Diagn Lab Immunol 1996; 3: 301-4.
19. Craston R, Koh M, McDermott A, Ray N, Prentice HG, Lowdell MW. Temporal dynamics of C69 expression on lymphoid cells. J Immunol Methods 1997; 209: 37-45.
20. Yacyshyn MBB, Poppema S, Berg A, et al. CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapy. Int J Cancer 1995; 61: 470-4.
21. Esplugues E, Sancho D, Vega-Ramos J, et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 2003; 197: 1093-106.
22. Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004; 19: 135-40.
23. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993; 53: 260-5.